Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Baxter
Medtronic
McKesson
Moodys

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204370


Email this page to a colleague

« Back to Dashboard

NDA 204370 describes VRAYLAR, which is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the VRAYLAR profile page.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.
Summary for 204370
Tradename:VRAYLAR
Applicant:Allergan
Ingredient:cariprazine hydrochloride
Patents:3
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 204370
Generic Entry Date for 204370*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 204370
Suppliers and Packaging for NDA: 204370
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370 NDA Allergan, Inc. 61874-115 61874-115-07 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-115-07)
VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370 NDA Allergan, Inc. 61874-115 61874-115-17 1 BLISTER PACK in 1 CARTON (61874-115-17) > 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK
Paragraph IV (Patent) Challenges for 204370
Tradename Dosage Ingredient NDA Submissiondate
VRAYLAR CAPSULE;ORAL cariprazine hydrochloride 204370 2019-09-17

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:Sep 17, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:May 24, 2022
Regulatory Exclusivity Use:TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)
Patent:⤷  Try it FreePatent Expiration:Sep 17, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
Patent:⤷  Try it FreePatent Expiration:Sep 17, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Merck
McKesson
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.